INTRODUCTION {#sec1-1}
============

Prostate cancer (PCa) is the second most frequent malignancy in men worldwide, accounting for more than 300 000 cancer-related deaths per year. In China, approximately 6.03% of adult males were suspected to have PCa in 2015, and the annual incidence of PCa in the Chinese population is increasing by 4.7%.[@ref1] Actionable molecular sequencing is a plausible and promising strategy for improving treatment results by targeted therapy. However, the incidence, prognosis, and treatment outcomes differ among ethnicities due to heterogeneity at the genetic and phenotypic levels.[@ref2][@ref3] Genetic and transcriptional alterations have been studied extensively in Western populations; however, little is known about the genomic aberrations associated with the pathogenesis of PCa in Chinese populations.

Next-generation sequencing (NGS) has enabled extensive profiling of genome-wide alterations during PCa tumorigenesis. Recent sequencing studies have revealed various somatically acquired genetic, epigenetic, and transcriptional changes in PCa, such as alterations in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (*PIK3CA*), tumor protein P53(*TP53*), speckle type BTB/POZ protein (SPOP), chromodomain helicase DNA-binding protein 1 (*CHD1*), and external transcribed spacer (*ETS*) transcription factor family.[@ref4] Notably, NGS approaches not only provide numerous insights into the molecular-based pathogenesis but also identify specific biomarkers for better patient stratification and targeted therapy. The hyperactivation of oncogenic signaling pathways, such as phosphatidylinositol 3-kinase (PI3K)/phosphatase and tensin homolog (PTEN)/AKT, is considered a prognostic biomarker for PCa and is closely correlated with advanced localized or metastatic disease.[@ref5] *SPOP*, *CHD1*, andETS transcription factor (*ERG*) statuses can be used for segregation, as they suggest future androgen receptor (AR) loss and possibly aggressive cancer development.[@ref6] DNA repair pathway defects indicate that patients would benefit from treatment with a poly(ADP)-ribose polymerase (PARP) inhibitor that has been approved by the US Food and Drug Administration for metastatic castration-resistant PCa monotherapy.[@ref7] Hence, discovering and validating genomic aberrations is urgently needed for PCa prediction, prognosis, and treatment in Chinese patients.

In this study, we performed a comprehensive molecular characterization of Chinese patients with PCa and explored correlations between identified genomic markers and clinical factors. We used quantitative real-time PCR (qRT-PCR) to detect the expression of focal PCa-related genes in 46 Chinese PCa samples. Moreover, we reanalyzed previously generated gene sequencing data[@ref8] and detected copy number variants (CNVs) by identifying clustered amplicons with significant changes in normalized log~2~ read depth.[@ref9] We provide an integrative overview of genetic/transcriptomic alterations in Chinese patients with PCa; these findings will improve our understanding of disease biology and have implications for personalized medicine.

PATIENTS AND METHODS {#sec1-2}
====================

 {#sec2-1}

### Patients and samples {#sec3-1}

The study included a total of 46 PCa samples collected at Nanfang Hospital (Guangzhou, China). All samples were histologically confirmed as PCa by two independent pathologists. Patients who received preoperative hormone therapy, chemotherapy, and radiotherapy were excluded. Detailed information for all samples is summarized in **[Supplementary Table 1](#T1){ref-type="table"}**. This study was approved by the Medical Ethics Committee of Nanfang Hospital (NFEC-2017-145), and the specimens were used with written informed consent by the Department of Pathology, Nanfang Hospital, in accordance with the Declaration of Helsinki.

###### 

Primer sequences used in our quantitative real-time polymerase chain reaction analysis

  Gene           Type                   Forward primer             Reverse primer
  -------------- ---------------------- -------------------------- ---------------------------
  AR             AR pathway             CCAGATCAGGGTTGAAGAGAAA     ATATGCTGGGTGACAAGAAGAG
  KLK2           AR pathway             GATAAGGCCGTGAGCAGAAA       GACCTGAACAAACCTCCTGTAA
  KLK3           AR pathway             GCTGGGAACTGCTATCTGTTAT     AGCAGGGAGAGAGTGAGATAG
  CAMKK2         AR pathway             CCCTAGACTCCACACAATAACC     AAGCCCTGGTTTCCTCATAC
  FKBP5          AR pathway             GTCTCCCACGTGTGTATTATGG     AATGGGCACCCTGTAGTTATTT
  ABCC4          AR pathway             GGAACTCCCACACTAAGGAATC     CTCTCCAGAGCACCATCTTTC
  STK39          AR pathway             CAGTTGAGTGTCAGCTGATGTA     GGAGGAAATGGGCAGAAAGA
  ZBTB10         AR pathway             GACATGGATCTCGACGTTATGG     CATCCCGAGGGAATTCTGTATC
  NUSAP1         Cell cycle             CCTCTTGTGATGAGACTGAGATAC   CAGTCTTGCACCTTCTCCTT
  KIF11          Cell cycle             CCGTTCTGGAGCTGTTGATAA      TGTTCTTTCTACAAGGGCAGTAA
  CDC20          Cell cycle             TTTGGCCAGTGGTGGTAATG       CCTTGATGCTGGGTGAATGT
  FOXM1          Cell cycle             GGGAACAACAAAGGCAATGG       GCAAAGATCAGGGAAGGTAAGA
  TMPRSS2: ERG   Subtype                CTGGAGCGCGGCAGGAA          GTAGGCACACTCAAACAACGACTGG
  ERG            Subtype                GAAGACTGGACTCAGGACATTT     GCTGTGTCCTTTCTCCTAACA
  ETV1           Subtype                GGTGGGTGGGAGTAATCTAAAC     CCCATCCCAAGCCTAAGTAAA
  ETV4           Subtype                GAAGAAAGGAACCTGGGATGAG     CCTAGGAAAGGGCAGAAGAAAG
  FLI1           Subtype                CATCTCCTACATGCCTTCCTAC     TGATGCGGCTCCAAAGAA
  CHD1           Subtype                TGGCAAAGGGAGAGAATATGG      CAACCTTGGCAGGAAGAGAT
  SPINK1         PCa main alterations   GCTTCTGAAGAGACGTGGTAAG     CCAAGGCACTGAGAAGAAAGA
  RAF1           PCa main alterations   CTCGTGGACAGAGAGATTCAAG     CTCCGTGCCATTTACCCTTAT
  PTEN           PCa main alterations   CTGCCAGCTAAAGGTGAAGATA     ATCACCACACACAGGTAACG
  PIK3CA         PCa main alterations   CTGGTTCAGCAGTGTGGTAA       CCTGCGTGGGAATAGCTAAA
  RB1            PCa main alterations   CTGTCTGAGCACCCAGAATTAG     GTCCAAATGCCTGTCTCTCAT
  MYC            PCa main alterations   CATACATCCTGTCCGTCCAAG      GAGTTCCGTAGCTGTTCAAGT
  NKX3-1         PCa main alterations   CGGAGACCCAAGTGAAGATATG     CAAAGAGGAGTGCTTCTCCAA
  EZH2           PCa main alterations   CTCGGTGTCAAACACCAATAAAG    AGTGCCAATGAGGACTCTAAAC
  KMT2D          PCa main alterations   ACCATGTGAAGAACAGGAAGAG     TCACCCTGGCTCAGATTAGA
  GAPDH          House keeping          CTCCTCACAGTTGCCATGTA       GTTGAGCACAGGGTACTTTATTG

AR: androgen receptor; PTEN: phosphatase and tensin homolog

### DNA extraction, amplicon capture, next-generation sequencing, and analysis {#sec3-2}

Samples for targeted NGS were dissected from 4-mm unstained sections, and genomic DNA was extracted using a GeneRead DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s protocol. The extracted DNA was quantified using a Qubit fluorometer (Invitrogen, Carlsbad, CA, USA). Genomic DNA with a yield of \>40 ng was used for library preparation. Amplicon enrichment was performed using the prostate cancer panel within the GeneRead DNAseq Targeted Panels V2 (Qiagen). Library preparation was performed using the GeneRead DNA Library Core Kit for Ion Torrent Proton (Qiagen) and barcoded with Ion Xpress™ Barcode Adapters (Thermo Fisher, Waltham, MA, USA). Sequencing of barcoded pools was performed using the Ion Torrent Proton, and the data were evaluated using Cloud-Based DNAseq Sequence Variant Analysis (Qiagen). Called variants were filtered by Ion Reporter (Thermo Fisher) to remove synonymous or noncoding variants and University of California, Santa Cruz (UCSC) common single-nucleotide polymorphisms (SNPs). High-confidence candidate somatic drivers were included in subsequent analyses.

For CNV determination, germline DNA (extracted from peripheral blood mononuclear cells) was collected from seven independent healthy males and sequenced to obtain the CNV baseline. CNV calling was performed using Cloud-Based DNAseq Sequence Variant Analysis. For targeted genes, CNVs were defined as clustered amplicons with significant changes in normalized log~2~ read depth, as previously reported.[@ref9] In particular, CNVs were evaluated as follows. 1) Amplicons were grouped into clusters of neighbors at a genomic locus (amplicon clustering). 2) The log~2~ read depth at each priming site was compared between sample and control datasets (filtered clustering). P-values were calculated by weighted *t*-tests (total read depth was used as the weight). 3) Only CNV calls with scores of \>50 indicated strong evidence (CNV identification).

### RNA extraction, reverse transcription, and PCR analysis {#sec3-3}

The same tissues for NGS were used to isolate RNA using the AllPrep DNA/RNA FFPE Kit (Qiagen) according to the manufacturer\'s protocol. The extracted RNA was quantified using a Qubit fluorometer (Thermo Fisher). Reverse transcription (RT) of 1 μg of RNA was performed using the QuantiTect Reverse Transcription Kit (Qiagen). The RT product was mixed with nuclease-free water, primers, and the SYBR Premix Ex Taq II Kit (Takara, Shiga, Japan). Quality PCR was performed using the CFX384 Touch Real-Time PCR system (Bio-Rad, Hercules, CA, USA). Data were analyzed using the 2^−ΔΔCt^ method, and normalized target gene expression was visualized using R statistical software (GraphPad Software, La Jolla, CA, USA).

### Statistical analyses {#sec3-4}

Kaplan--Meier analysis was performed using R statistical software. Disease-free survival (DFS) was defined as the time from diagnosis to recurrence or date of last follow-up. The log-rank test was used to calculate the P- values or the Kaplan--Meier analysis.

A large prostate cancer dataset from the Cancer Genome Atlas (TCGA), with both gene expression and clinical follow-up data, was used for the correlation analysis. Level 3 gene expression data were downloaded from TCGA data portal (<https://tcga-data.nci.nih.gov/tcga/>). RNA-seq by Expectation-Maximization (RSEM) normalized expression data were obtained.

Correlations between the recurrently altered genes and clinical parameters were evaluated using Fisher\'s tests; gene expression correlations were evaluated based on Pearson\'s correlation coefficients, as determined using R statistical software.

RESULTS {#sec1-3}
=======

 {#sec2-2}

### Application of integrative genetic/transcriptomic assays for Chinese clinical formalin-fixed paraffin-embedded (FFPE) PCa samples {#sec3-5}

To identify the genetic and transcriptomic spectra of genes associated with the pathogenesis of PCa in Chinese patients, we performed integrative DNA- and RNA-based assays requiring only approximately 50 ng of FFPE DNA and 500 ng of FFPE RNA. The assays consist of a multiplex PCR-based panel for gene sequencing and a qRT-PCR array for the detection of gene expression. The gene sequencing panel was used for target enrichment of the exonic regions of the 32 most commonly mutated genes in human PCa samples, and the amplification or deletion of these genes was evaluated as described previously.[@ref9] The qRT-PCR assay included 28 genes, including robust housekeeping genes, AR transcriptional modules, cell cycle-related genes, and genes defining molecular subtypes or molecular drivers based on previous transcriptomic studies (**[Supplementary Table 1](#T1){ref-type="table"}**). The integrative assays were performed using samples obtained from a cohort of 46 Chinese patients with PCa after radical prostatectomy or transurethral resection of the prostate (**[Supplementary Table 2](#T2){ref-type="table"}**).

###### 

46 Chinese prostate cancer samples assessed by target gene sequence and quantitative real-time polymerase chain reaction

  Sample ID   Target NGS   RT-qPCR   Age   Site   Percentage tumor   Gleason score   TNM stage   tPSA     Disease free status   NCCN risk stratification   EAU risk classification
  ----------- ------------ --------- ----- ------ ------------------ --------------- ----------- -------- --------------------- -------------------------- -------------------------
  PR101       Yes          Yes       68    RP     30                 8               T3aN0Mx     158.69   Disease free          High                       Locally advanced
  PR102       Yes          Yes       73    RP     50                 6               T3aN0Mx     \>50     Recurred              High                       Locally advanced
  PR103       Yes          Yes       66    RP     50                 7               T2aN0M0     16.9     Disease free          Favorable intermediate     Intermediate risk
  PR104       Yes          Yes       61    RP     30                 8               T2aN0M0     7.027    Disease free          High                       High risk
  PR105       Yes          Yes       49    RP     70                 7               T4N0Mx      \>100    Disease free          Very high                  Locally advanced
  PR106       Yes          Yes       68    RP     50                 7               T3aN0Mx     \>100    Recurred              High                       Locally advanced
  PR107       Yes          Yes       71    RP     30                 6               T2aN0M0     9.3      Disease free          Low                        Low risk
  PR108       Yes          Yes       67    RP     60                 7               T2aN0M0     9.85     Disease free          Favorable intermediate     Intermediate risk
  PR109       Yes          Yes       67    RP     70                 4               T2aN0Mx     3.143    Disease free          Low                        Low risk
  PR110       Yes          No^\*^    67    RP     80                 10              T4N0Mx      21.523   Recurred              Very high                  Locally advanced
  PR111       Yes          Yes       68    RP     70                 7               T4N0Mx      9.101    Recurred              Very high                  Locally advanced
  PR112       Yes          Yes       71    RP     50                 9               T3bNxM1     17.95    Recurred              Metastatic                 Metastatic
  PR113       Yes          No^\*^    66    RP     80                 7               T4N0Mx      9.66     Recurred              Very high                  Locally advanced
  PR114       Yes          Yes       67    RP     70                 7               T2bNxM0     43.57    Disease free          High                       High risk
  PR115       Yes          Yes       63    RP     90                 4+3+5           T2cN0M0     20.37    Disease free          High                       High risk
  PR201       Yes          Yes       73    RP     70                 7               T2bN0M0     18.58    Disease free          Unfavorable intermediate   Intermediate risk
  PR202       Yes          Yes       54    RP     80                 8               T4N0Mx      114.93   Recurred              Very high                  Locally advanced
  PR203       Yes          Yes       68    RP     90                 7               T2cN0M0     8.76     Disease free          Unfavorable intermediate   High risk
  PR205       Yes          Yes       65    RP     50                 8               T2cN0M0     13.86    Disease free          High                       High risk
  PR206       Yes          Yes       73    RP     40                 8               T3bN0M0     35.16    Recurred              Very high                  Locally advanced
  PR207       Yes          Yes       62    RP     40                 7               T2cN0M0     6.41     Recurred              Unfavorable intermediate   High risk
  PR208       Yes          Yes       49    RP     80                 6               T2cN0M0     123.12   Recurred              High                       High risk
  PR210       Yes          Yes       73    RP     60                 8               T2bN0M0     22.9     Recurred              High                       High risk
  PR212       Yes          Yes       60    RP     60                 7               T2cN0M0     43.03    Disease free          High                       High risk
  PR213       Yes          Yes       69    RP     70                 10              T3aN0M0     3.79     Disease free          Very high                  Locally advanced
  PR214       Yes          Yes       57    RP     70                 7               T2bN0M0     12       Disease free          Favorable intermediate     Intermediate risk
  PR215       Yes          Yes       65    RP     60                 6               T2cN0M0     8.11     Disease free          Favorable intermediate     High risk
  PR302       Yes          Yes       60    RP     70                 6               T2aN0M0     10.88    Disease free          Favorable intermediate     Intermediate risk
  PR304       Yes          Yes       75    RP     70                 7               T2bN0M0     4.65     Disease free          Unfavorable intermediate   Intermediate risk
  PR305       Yes          Yes       80    RP     70                 6               T2bN0M0     7.01     Disease free          Favorable intermediate     Intermediate risk
  PR306       Yes          Yes       66    RP     90                 7               T3aN0M0     98.16    Disease free          High                       Locally advanced
  PR307       Yes          Yes       67    RP     50                 5               T2bN0M0     5.81     Disease free          Favorable intermediate     Intermediate risk
  PR308       Yes          Yes       56    RP     70                 7               T2aN0M0     13.7     Disease free          Favorable intermediate     Intermediate risk
  PR309       Yes          No^\*^    59    RP     60                 7               T2N1M1      7.69     Recurred              Metastatic                 Metastatic
  PR310       Yes          Yes       63    RP     60                 9               T2cN0M0     9.22     Recurred              High                       High risk
  PR311       Yes          Yes       63    RP     95                 8               T2cN1M0     67.61    Disease free          Regional                   Locally advanced
  PR312       Yes          Yes       52    RP     40                 7               T2cN0M0     19.22    Recurred              Unfavorable intermediate   High risk
  PR313       Yes          Yes       77    TURP   65                 7               T4N1Mx      157.86   Disease free          Regional                   Locally advanced
  PR315       Yes          Yes       77    TURP   95                 8               T2cNxM1     \>500    Disease free          Metastatic                 Metastatic
  PR401       Yes          Yes       67    RP     60                 6               T2aN0M0     9.27     Disease free          Low                        Low risk
  PR403       Yes          Yes       49    RP     70                 6               T2bN0M0     9.21     Disease free          High                       High risk
  PR404       Yes          Yes       44    RP     70                 7               T2bN0M0     24.4     Disease free          High                       High risk
  PR414       Yes          No        72    RP     40                 8               T2cN0M0     91.48    Recurred              Favorable intermediate     Intermediate risk
  PRY01       Yes          Yes       59    RP     30                 7               T2N0M0      14.082   Disease free          Favorable intermediate     Intermediate risk
  PRY02       Yes          Yes       63    RP     30                 6               T2bN0M0     12.18    Disease free          Favorable intermediate     Intermediate risk
  PRY04       Yes          Yes       72    RP     30                 7               T2cN0M0     20.2     Recurred              High                       High risk

\*The samples didn't perform gene expression analysis by qRT-PCR due to low RNA quality. Specimen type: RRP: radical retropubic prostatectomy; TURP: transurethral resection of the prostate. qRT-PCR: quantitative real-time polymerase chain reaction; NGS: next-generation sequencing; TNM: Tumor-node-metastasis; tPSA: total PSA; RP: radical prostatectomy; NCCN: National Comprehensive Cancer Network; EAU: European Association of Urology

### Mutation and copy number variant detection by targeted gene sequencing {#sec3-6}

Ion Torrent NGS after multiplex PCR-based targeted enrichment was applied to 46 FFPE PCa samples, yielding an average of 6 243 762 mapped reads and an average coverage of 3527× (1156--5419×) over targeted bases per sample. The complete coverage details are provided in **[Supplementary Table 3](#T3){ref-type="table"}**. An initial 5909 variants were filtered for quality, SNPs, and functional relevance. As described previously,[@ref8] we identified 245 nonsynonymous (missense, in-frame deletion, nonsense, stop-loss, and frameshift) mutations with an allele frequency of ≥3% in all sequencing specimens (average: 5; range: 1--34) across 27 genes. All high-confidence mutations are shown in a heatmap in **[Figure 1](#F1){ref-type="fig"}** and are detailed in **Supplementary Table 4**. The most frequently mutated genes were lysine (K)-specific methyltransferase 2D (*KMT2D*, 63.04%), zinc finger homeobox 3 (*ZFHX3*, 50.00%), A-kinase anchoring protein 9 (*AKAP9*, 32.61%), GLI family zinc finger 1 (*GLI1*, 32.61%), thrombospondin type 1 domain containing 7B (*THSD7B*, 19.57%), *APC* regulator of WNT signaling pathway (APC, 15.22%), cyclin-dependent kinase 12 (*CDK12*, 15.22%), lysine demethylase 4B (KDM4B, 15.22%), mediator complex subunit 12 (*MED12*, 15.22%), and zinc finger protein 595 (*ZNF595*, 15.22%).

###### 

Sequencing statistics for Chinese prostate cancer samples assessed on target gene sequence

  Sample ID   Total reads   Read depth   Percentage of bases covered at ³100×   SNPs/MNPs   Insertions/deletions
  ----------- ------------- ------------ -------------------------------------- ----------- ----------------------
  PR101       5068352       2830         98                                     98          6
  PR102       5947960       3373         98                                     104         4
  PR103       5286208       3106         98                                     105         6
  PR104       6744522       3889         98                                     95          8
  PR105       6929606       4076         99                                     109         6
  PR106       5894989       3467         98                                     105         6
  PR107       5911356       3381         98                                     112         9
  PR108       5918910       3321         98                                     117         11
  PR109       6543896       3709         98                                     104         5
  PR110       5653814       3064         96                                     111         7
  PR111       6314382       3550         98                                     114         10
  PR112       4459067       2496         98                                     111         9
  PR113       6677205       3636         98                                     150         11
  PR114       5470762       3094         98                                     100         7
  PR115       9498650       5419         99                                     126         8
  PR201       3145871       1584         92                                     176         9
  PR202       2801865       1572         95                                     129         9
  PR203       2633500       1488         98                                     114         7
  PR205       9233792       4882         96                                     153         11
  PR206       7980130       4619         98                                     121         10
  PR207       7660193       4497         99                                     141         11
  PR208       8228356       4574         98                                     112         9
  PR210       7929129       4429         98                                     121         11
  PR212       7932509       4595         98                                     123         11
  PR213       7707601       4476         98                                     121         14
  PR214       6895340       4048         98                                     117         7
  PR215       8254890       4630         97                                     107         8
  PR302       5687529       3129         96                                     113         7
  PR304       7384117       4227         98                                     134         8
  PR305       5473565       3106         98                                     127         9
  PR306       6107461       3432         97                                     105         7
  PR307       6090712       3486         98                                     139         5
  PR308       6220821       3516         98                                     102         5
  PR309       7586732       4021         95                                     206         8
  PR310       4196760       2343         97                                     116         5
  PR311       6496237       3710         98                                     119         9
  PR312       6120013       3559         98                                     126         6
  PR313       6981974       3865         97                                     137         8
  PR315       5432214       3133         98                                     102         5
  PR401       5855582       3217         95                                     121         7
  PR403       5291636       2727         98                                     111         10
  PR404       9418627       5355         98                                     130         10
  PR414       7055318       4060         99                                     106         6
  PRY01       8761095       5121         99                                     146         13
  PRY02       1989740       1156         98                                     104         10
  PRY04       2340079       1305         97                                     94          7

SNPs: single-nucleotide polymorphisms; MNPs: multiple-nucleotide polymorphisms

![Integrative molecular profiling of Chinese FFPE prostate cancer (PCa) samples. A heatmap of somatic alterations for each sample is shown. Clinicopathological information is provided in the header, including Gleason score, T stage, tumor percentage, and molecular subtype based on qRT-PCR analysis. High-level somatic CNVs and mutations are indicated according to the legend. FFPE: formalin-fixed paraffin-embedded; qRT-PCR: quantitative real-time polymerase chain reaction; CNVs: copy number variants. All abbreviated names of genes are defined in **[Supplementary Table 6](#T5){ref-type="table"}**.](AJA-22-162-g001){#F1}

Using an approach adapted from multiplexed PCR-based targeted Ion Torrent NGS data,[@ref9] we simultaneously assessed CNVs in 25 genes, yielding a total of 312 high-level CNVs across the 46 PCa specimens (average: 7 high-level CNVs per sample; range: 0--15). A copy number heatmap for all samples is shown in **[Figure 1](#F1){ref-type="fig"}**.

### Assessment of critical PCa transcriptomic alterations by qRT-PCR {#sec3-7}

We performed qRT-PCR using RNA isolated from the sequencing cohort of 43 FFPE PCa samples (the sequencing samples, excluding those with low RNA quality). Normalized target gene expression is shown in **[Figure 2](#F2){ref-type="fig"}**. Combined with target sequencing, we performed basic PCa molecular subtyping for the 43 Chinese patients (**Figure [1](#F1){ref-type="fig"}** and **[2](#F2){ref-type="fig"}**). *TMPRSS2:ERG* was detected in nine cancer samples, which showed approximately 70-fold greater *TMPRSS2:ERG* expression than the median of the 34 other *TMPRSS2:ERG*-negative samples. Two samples showed marked ETS variant 4 (*ETV4*) overexpression, indicating the presence of a gene fusion in this *ETS* family member. Overexpression of serine peptidase inhibitor, Kazal type 1 (*SPINK1*), was identified in four samples (the SPINK1^+^ subtype). Moreover, by targeted gene sequencing, we observed high-confidence *SPOP* mutations in samples PR110, PR112, and PR203, each of which was *ETS*-negative by qRT-PCR. Among these samples, PR203 also showed high *SPINK1* expression, suggesting the overlap of these alterations.

![Gene expression signatures of PCa assessed by qRT-PCR. Unsupervised hierarchical clustering of gene expression signatures for PCa-related genes. Normalized target gene expression (log~2~) for 28 robust target genes assessed by the qRT-PCR panel. qRT-PCR: quantitative real-time polymerase chain reaction; PCa: prostate cancer. All abbreviated names of genes are defined in **[Supplementary Table 6](#T5){ref-type="table"}**.](AJA-22-162-g002){#F2}

###### 

Clinical features and driver alterations in Chinese prostate cancer patients

  Classification                 All (n)   PTEN loss function mutation and deletions PIK3CA amplification   NCOA2 amplification SPOP mutation   AR activity   MYC amplification   RB1 deletion   Cell cycle-related gene expression   ETS fusion status   APC mutation/deletion   GLI1 mutation                                                                                                               
  ------------------------------ --------- ---------------------------------------------------------------- ----------------------------------- ------------- ------------------- -------------- ------------------------------------ ------------------- ----------------------- --------------- ---- ---- ------- ---- ---- ----------- ---- ---- ------- ---- ---- ----------- ---- ---- ------- ---- ---- -----------
  Age (year)                                                                                                                                                                                                                                                                                                                                                                                                  
   ≤60                           12        1                                                                11                                  0.035^\*^     4                   8              0.416                                7                   4                       0.310           7    5    1.000   2    10   0.041^\*^   6    5    0.736   2    10   0.701       5    7    1.000   4    8    1.000
   \>60                          34        15                                                               19                                                6                   28                                                  14                  18                                      21   13           19   15               15   17           9    25               15   19           11   23   
  Total PSA levels (ng ml^−1^)                                                                                                                                                                                                                                                                                                                                                                                
   \<10                          17        7                                                                10                                  0.787         6                   11             0.110                                8                   7                       0.538           9    8    0.687   6    11   0.146       8    7    0.925   5    12   0.824       7    10   0.477   8    9    0.155
   10--20                        10        3                                                                7                                                 0                   10                                                  6                   4                                       6    4            3    7                5    5            2    8                6    4            1    9    
   \>20                          19        6                                                                13                                                4                   15                                                  7                   11                                      13   6            12   7                8    10           4    15               7    12           6    13   
  Gleason score                                                                                                                                                                                                                                                                                                                                                                                               
   \<7                           11        4                                                                7                                   1.000         4                   7              0.427                                6                   5                       0.335           6    5    0.860   4    7    0.555       5    6    0.632   4    7    0.505       4    7    0.865   5    6    0.207
   7                             21        7                                                                14                                                4                   17                                                  11                  8                                       13   8            9    12               8    11           5    16               9    12           8    13   
   \>7                           14        5                                                                9                                                 2                   12                                                  4                   9                                       9    5            8    6                8    5            2    12               7    7            2    12   
  T stage                                                                                                                                                                                                                                                                                                                                                                                                     
   pT2                           33        12                                                               21                                  0.703         9                   24             0.335                                16                  16                      0.349           20   13   0.714   12   21   0.066       15   17   0.687   6    27   0.030^\*^   14   19   1.000   11   22   0.699
   pT3                           7         3                                                                4                                                 0                   7                                                   2                   5                                       5    2            6    1                3    4            1    6                3    4            3    4    
   pT4                           6         1                                                                5                                                 1                   5                                                   3                   1                                       3    3            3    3                3    1            4    2                3    3            1    5    
  Distance metastasis                                                                                                                                                                                                                                                                                                                                                                                         
   Yes                           3         0                                                                3                                   0.541         1                   2              0.529                                1                   1                       1.000           2    1    1.000   2    1    0.162       2    0    0.233   0    3    1.000       3    0    0.075   3    0    0.030^\*^
   No                            43        16                                                               27                                                9                   34                                                  20                  21                                      26   17           10   33               19   22           11   32               17   26           12   31   
  NCCN risk stratification                                                                                                                                                                                                                                                                                                                                                                                    
   Low                           3         1                                                                2                                   0.173         0                   3              0.607                                3                   0                       0.314           1    2    0.378   2    1    0.006^\*^   2    1    0.314   1    2    0.352       0    3    0.099   1    2    0.263
   Favorable intermediate        11        3                                                                8                                                 3                   8                                                   6                   5                                       4    7            0    11               4    7            3    8                5    6            4    7    
   Unfavorable intermediate      5         4                                                                1                                                 2                   3                                                   3                   2                                       4    1            3    2                3    2            1    4                4    1            1    4    
   High                          15        7                                                                8                                                 2                   13                                                  4                   11                                      11   4            10   5                6    9            2    13               5    10           5    10   
   Very high                     7         1                                                                6                                                 1                   6                                                   3                   2                                       4    3            3    4                4    1            4    3                3    4            1    6    
   Regional                      2         0                                                                2                                                 1                   1                                                   1                   1                                       2    0            1    1                0    2            0    2                0    2            0    2    
   Metastatic                    3         0                                                                3                                                 1                   2                                                   1                   1                                       2    1            2    1                2    0            0    3                3    0            3    0    
  EAU risk classificiton                                                                                                                                                                                                                                                                                                                                                                                      
   Low risk                      3         1                                                                2                                   0.376         0                   3              0.862                                3                   0                       0.078           1    2    0.242   2    1    0.022^\*^   2    1    0.512   1    2    0.183       0    3    0.210   1    2    0.165
   Intermediate risk             12        3                                                                9                                                 3                   9                                                   8                   4                                       5    7            1    11               4    8            4    8                6    6            4    8    
   High risk                     15        8                                                                7                                                 4                   11                                                  4                   11                                      12   3            8    7                8    7            1    14               6    9            4    11   
   Locally advanced              13        4                                                                9                                                 2                   11                                                  5                   6                                       8    5            8    5                5    6            5    8                5    8            3    10   
   Metastatic                    3         0                                                                3                                                 1                   2                                                   1                   1                                       2    1            2    1                2    0            0    3                3    0            3    0    

\**P* \< 0.05. EAU: European Association of Urology; AR: androgen receptor; ETS: external transcribed spacer; PSA: prostate-specific antigen; NCCN: National Comprehensive Cancer Network; APC: APC regulator of WNT signaling pathway; GLI1: GLI family zinc finger 1

###### 

The official full name of genes listed in the figures

  Gene abbreviation   Official full name
  ------------------- ------------------------------------------------------------------------
  KMT2D               Lysine methyltransferase 2D
  ZFHX3               Zinc finger homeobox 3
  AKAP9               A-kinase anchoring protein 9
  GLI1                GLI family zinc finger 1
  THSD7B              Thrombospondin type 1 domain containing 7B
  APC                 APC regulator of WNT signaling pathway
  CDK12               Cyclin-dependent kinase 12
  KDM4B               Lysine demethylase 4B
  MED12               Mediator complex subunit 12
  ZNF595              Zinc finger protein 595
  PIK3CA              Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
  ZNF473              Hypoxia inducible factor 1 subunit alpha
  NCOA2               Nuclear receptor coactivator 2
  PDZRN3              PDZ domain containing ring finger 3
  SCN11A              Sodium voltage-gated channel alpha subunit 11
  SYNE3               Spectrin repeat containing nuclear envelope family member 3
  IKZF4               IKAROS family zinc finger 4
  SPOP                Speckle type BTB/POZ protein
  TP53                Tumor protein p53
  AR                  Androgen receptor
  NKX3-1              NK3 homeobox 1
  NRCAM               Neuronal cell adhesion molecule
  PTEN                Phosphatase and tensin homolog
  TFG                 TRK-fused gene
  CDKN2A              Cyclin-dependent kinase inhibitor 2A
  NIPA2               NIPA magnesium transporter 2
  RB1                 RB transcriptional corepressor 1
  OR5L1               Olfactory receptor family 5 subfamily L member 1
  MYC                 MYC proto-oncogene, bHLH transcription factor
  TBX20               T-box 20
  KLK2                Kallikrein-related peptidase 2
  KLK3                Kallikrein-related peptidase 3
  CAMKK2              Calcium/calmodulin-dependent protein kinase kinase 2
  FKBP5               FKBP prolyl isomerase 5
  ABCC4               ATP-binding cassette subfamily C member 4
  STK39               Serine/threonine kinase 39
  ZBTB10              Zinc finger and BTB domain containing 10
  NUSAP1              Nucleolar and spindle-associated protein 1
  KIF11               KIF11
  CDC20               Cell division cycle 20
  FOXM1               Forkhead box M1
  TMPRSS2:ERG         transmembrane serine protease 2: ETS transcription factor ERG
  ERG                 ETS transcription factor ERG
  ETV1                ETS variant 1
  ETV4                ETS variant 4
  FLI1                Fli-1 proto-oncogene
  CHD1                Chromodomain helicase DNA-binding protein 1
  SPINK1              Serine peptidase inhibitor, Kazal type 1
  RAF1                Raf-1 proto-oncogene
  EZH2                Enhancer of zeste 2 polycomb repressive complex 2 subunit

PTEN: phosphatase and tensin homolog; AR: androgen receptor; ETS: external transcribed spacer

AR-targeted genes were included based on previous microarray analyses of genes regulated by androgens in PCa.[@ref10] Our results showed that the AR signature was heterogeneous in all treatment-naïve PCa specimens. AR activity might predict the response to therapies targeting the AR axis. PR315 and PRY04 had markedly lower AR activity than that of other samples, suggesting different responses to anti-androgen therapy compared with those of samples with high AR activity.

In addition, four cell cycle-related genes, nucleolar and spindle-associated protein 1 (*NUSAP1*), kinesin family member 11 (*KIF11*), cell division cycle 20 (*CDC20*), and forkhead box M1 (*FOXM1*), were evaluated as indicators of cell proliferation, a fundamental aspect of tumor biology.[@ref11] Most of the samples showed relatively low expression of cell cycle progression genes, suggesting low aggressiveness in the early stages of PCa. Our results support the use of qRT-PCR as a complementary approach to target gene sequencing for assessing critical transcriptomic events in PCa.

### Molecular features correlated with clinical characteristics and prognosis {#sec3-8}

We subdivided the genomic aberrations in Chinese PCa patients identified by integrative genetic/transcriptomic assays into nine specific pathways (**[Supplementary Table 5](#T4){ref-type="table"}**). These molecules are commonly altered in Western patients with PCa and have clinical implications.[@ref12] We analyzed the correlations between these genomic aberrations and clinicopathological characteristics, including prostate-specific antigen (PSA) level, Gleason score, T stage, distant metastasis, and clinical risk stratification from the National Comprehensive Cancer Network (NCCN) and the European Association of Urology (EAU). As shown in **[Supplementary Table 5](#T4){ref-type="table"}**, activation of the PI3K/AKT/PTEN pathway and deletion of RB transcriptional corepressor 1 (*RB1*) were dramatically correlated with older age (*P* = 0.035 and *P* = 0.041, respectively). The *ETS* fusion was more common in patients at an advanced T stage (*P* = 0.030). Notably, an increased risk of progression was found in patients with the *RB1* deletion, both in NCCN risk stratification (*P* = 0.006) and in EAU risk classification (*P* = 0.022). In addition, recurrent mutated or copy number-altered genes were included in the correlation analysis. *GLI* mutation was notably correlated with distant metastasis (*P* = 0.030).

The prognostic impacts of the five specific pathways and recurrently altered genes were assessed. Log-rank tests were used to analyze the outcome for each individual subtype. *MYC* proto-oncogene (MYC) amplification (*P* = 0.036), *RB1* deletion (*P* = 0.029), *APC* mutation/deletion (*P* = 0.032), and *CDK12* mutation (*P* = 0.029) were associated with worse progression-free survival (PFS) in the 46 Chinese patients with PCa (**[Figure 3](#F3){ref-type="fig"}**). Furthermore, we explored the clinical characteristics related to prognosis in Chinese populations. As expected, PFS decreased with increasing T stage (*P* = 0.0024), distant metastasis (*P* = 0.0012), NCCN risk stratification (*P* = 0.0011), and EAU risk classification (*P* = 0.00039) (**Supplementary Figure 1**). These results indicated a high predictive value of these risk factors, which may contribute to clinical decision-making in Chinese patients with PCa.

### KMT2D is positively correlated with the AR signaling pathway in PCa {#sec3-9}

Another advantage of the integrative genetic/transcriptomic assay is the ability to explore the correlations underlying recurrently altered genes. We performed a correlation analysis of the expression of the 27 robust target genes across all samples. We observed correlated expression of genes within the AR signaling pathway and cell cycle progression modules (**[Figure 4a](#F4){ref-type="fig"}**). In particular, positive correlations were identified between *KMT2D* and *AR* (*r* = 0.31, *P* = 0.046), the AR downstream target calcium/calmodulin-dependent protein kinase kinase 2 (*CAMKK2*) (*r* = 0.45, *P* = 0.046), the cell cycle progression gene *CDC20* (*r* = 0.32, *P* = 0.037), and *SPINK1* (*r* = 0.40, *P* = 0.008) (**[Figure 4b](#F4){ref-type="fig"}**). Because the AR signaling pathway is indispensable for PCa carcinogenesis, we further validated the correlation between *KMT2D* and *AR* signaling using the Cancer Genome Atlas Prostate Adenocarcinoma (TCGA-PRAD) data. Consistent with our qRT-PCR results, *KMT2D* expression was strongly correlated with *AR* mRNA levels (*r* = 0.70, *P* \< 0.001; **[Figure 4c](#F4){ref-type="fig"}** left) and AR protein levels (*r* = 0.32, *P* \< 0.001; **[Figure 4c](#F4){ref-type="fig"}** right). Patients with *AR-V7* had higher *KMT2D* expression (*P* = 0.036; **[Figure 4d](#F4){ref-type="fig"}**), suggesting that KMT2D contributes to the AR splice variants. These findings highlight the close linkage between KMT2D and AR signaling and suggest that KMT2D plays a critical role in the activation of the AR axis in PCa.

![*MYC* amplification, *RB1* deletion, *APC* mutation/deletion, and *CDK12* mutation are linked to worse prognosis in our cohort. Survival analysis was performed in Chinese PCa patients treated according to the presence or absence of (**a**) *MYC* amplification, (**b**) *RB1* deletion, (**c**) *APC* mutation/deletion, and (**d**) *CDK12* mutation. PCa: prostate cancer; MYC: MYC proto-oncogene, bHLH transcription factor; RB1: RB transcriptional corepressor 1; APC: APC regulator of WNT signaling pathway; CDK12: Cyclin-dependent kinase 12.](AJA-22-162-g003){#F3}

![*KMT2D* is positively correlated with the AR signaling pathway in PCa. (**a**) Heatmap of correlations (*r*) between normalized gene expression for the 27 robust target genes across all samples shown in Figure 2. (**b**) *KMT2D* mRNA levels were positively correlated with *AR, CAMKK2, CDC20*, and *SPINK1* expression in PCa tissues in our cohort. (**c**) *KMT2D* mRNA levels were positively correlated with both gene and protein expression of AR in TCGA-PRAD. (**d**) mRNA expression of *KMT2D* in AR-V7-positive and AR-V7-negative cases from TCGA-PRAD. PCa: prostate cancer; TCGA-PRAD: The Cancer Genome Atlas Prostate Adenocarcinoma. All abbreviated names of genes are defined in **[Supplementary Table 6](#T5){ref-type="table"}**.](AJA-22-162-g004){#F4}

DISCUSSION {#sec1-4}
==========

We used a rapid, robust, and high-throughput approach for the characterization of gene mutations, copy number variants, and crucial transcriptomic events in Chinese patients with PCa by combined multiple-PCR-based deep NGS and qRT-PCR. This integrative assay required only 50 ng of DNA and 500 ng of RNA, which can be co-isolated from most routine clinical samples, making it practical for academic research settings as well as routine clinical settings. In this study, we added to the current knowledge of the genetic heterogeneity of prostate tumors among ethnic populations and identified correlations between clinical and prognostic factors and recurrently altered genes, providing a basis for therapeutic decisions. Moreover, we observed a close relationship between *KMT2D* and AR signaling in a gene co-expression analysis, highlighting the important role of *KMT2D* in the activation of the AR axis in PCa.

Our findings expand our understanding of the ethnicity-specific molecular landscape of PCa. As a heterogeneous disease, previous studies have reported notable disparities in PCa epidemiology among ethnic groups.[@ref13] Emerging evidence suggests that these differences might be the result of distinct molecular characteristics.[@ref14][@ref15] Ren *et al*.[@ref16] identified salient genetic characteristics of PCa in Chinese patients. Similarly, the molecular profiles of Chinese patients with PCa identified in our cohort differed from that of Western patients. The most frequently mutated genes were *KMT2D, ZFHX3, AKAP9*, and *GLI1* in our cohort; recurrently mutated genes in Western populations are *SPOP*, titin (*TTN*), *TP53*, mucin 16 (*MUC16*), *MED12*, and Forkhead Box A1 (*FOXA1*).[@ref17] These results might be due to either *de novo* ethnicity-specific mutations in Chinese patients or high-depth sequencing effects. Asian and Western populations have distinct genetic polymorphisms,[@ref18][@ref19] familial aggregation,[@ref20] and diet.[@ref21] Basic science and epidemiological studies have demonstrated that these factors have a role in the clinical heterogeneity of PCa.[@ref22] Thus, the differences in these factors might influence the tumor genome and contribute to the ethnic genetic heterogeneity of PCa. Moreover, unlike other large-scale sequencing studies in Western patients, in which the sequencing depth is about 100×, in this study, we focused on 32 PCa-correlated genes and the average sequencing depth was approximately 3527×. The higher sequencing depth can remarkably increase the sensitivity of single-nucleotide variant detection;[@ref23] hence, the high coverage might account for the high mutation frequency of some genes in our cohort.

In addition to mutation, using an algorithm developed by Grasso *et al*.,[@ref9] we detected CNVs in our amplicon-based sequencing data. We observed copy number gains of *KMT2D, AKAP9, MYC*, and *GLI* and copy number losses of *PTEN*, *RB1*, and *APC* in Chinese patients. *PTEN* inactivation and copy number deletions account for the majority of PTEN loss-of-function cases.[@ref5] We found a low frequency of these genomic changes, *i.e*., 23.9% (11/46) in our cohort, compared with approximately 40% in Western samples.[@ref15] *MYC* amplification and *RB1* deletion are two major CNVs detected in multiple genomic analyses.[@ref12] We also found *MYC* gains (60.9%, 28/46) and *RB1* deletions (45.7%, 21/46) in our samples. However, the frequencies were higher than those in Western populations, in which *MYC* amplification and *RB1* were deleted in 7.4% (37/498) and 16.3% (81/498) cases from TCGA-PRAD, respectively. For critical transcriptomic events, we identified a lower frequency of the *ETS* fusion (23.9%, 11/46) in our patients than in Caucasian patients (with a prevalence of approximately 50%).[@ref24] The results of other large-scale studies further support the low frequency of the *ETS* fusion in Asian patients,[@ref14][@ref15][@ref25] indicating regional differences in molecular subtypes.

Furthermore, we identified clinical associations for the recurrently altered genes. Copy number deletion of *RB1* was remarkably correlated with a high risk of disease progression. *ETS* fusion and *GLI1* mutations were more common in patients with a higher T stage and distant metastasis, respectively, than in other patients. Importantly, poor prognosis was associated with various alterations, including *MYC* amplification, *RB1* deletion, *APC* mutation or deletion, and *CDK12* mutation. *MYC* and RB1 are involved in the regulation of the cell cycle; amplification of *MYC* prompts progression from G1 to S phase,[@ref17][@ref26] and MYC amplification status is predictive of biochemical recurrence after prostatectomy.[@ref27] However, its mRNA or protein levels show weak prognostic ability.[@ref28] *RB1* is a critical negative regulator of the G1--S checkpoint and is responsible for repressing E2F family transcription factors.[@ref29] According to a recent study, *RB1* deletion occurs early in PCa, prior to subclonal diversification.[@ref30] Consistent with our results, a large PCa tissue microarray study indicated that the deletion of RB1 is linked to an adverse phenotype and poor prognosis in this disease.[@ref31] *APC* is a multifunctional protein and is as a negative regulator of the Wnt pathway.[@ref32] The inactivation of APC by mutations or hypermethylation is associated with tumor aggressiveness.[@ref33][@ref34] In Chinese populations, Geng *et al*.[@ref35] showed that APC mutations are associated with both PCa progression and all-cause mortality. CKD12 is a cyclin-dependent kinase; however, Wu *et al*.[@ref36] found that inactivation of CDK12 could define a distinct subtype of PCa, leading to increased neoantigen burden and T cell infiltration. Moreover, the loss of CDK12 is associated with genomic instability and predicts a worse poor prognosis in breast cancer.[@ref37] These findings further indicated that these genomic events are associated with clinical parameters and might serve as biomarkers in Chinese patients. However, given the small sample size, an independent cohort of patients is needed to confirm these results in the future.

Our integrative genetic/transcriptomic assays might also have utility for personalized medicine. The five main pathways involved in our analysis have clinical implications, and drugs targeting these alterations have been developed.[@ref12] For instance, the PI3K/AKT/PTEN pathway was upregulated in 34.78% of samples in our cohort. Therapeutically, to target this pathway, pan-PI3K and dual PI3K--mTOR inhibitors have been developed, and the AKT-targeting drugs BKM120 and MK-2206 show clinical efficacy in PCa.[@ref6] Cancer immunotherapies have become a revolutionized approach to the treatment of cancers, including PCa.[@ref38] The inactivation of CDK12 delineates a distinct immunogenic class of PCa, and a clinical study showed that patients with metastatic PCa who harbor a biallelic *CDK12* loss have a higher likelihood of response to immunotherapy.[@ref36] In our cohort, 15.22% (7/46) of patients had *CDK12* mutations. Among them, PR110, PR113, PR206, and PR309 were in an advanced state and relapsed after radical prostatectomy. These patients might benefit from immune checkpoint inhibitors after progression to the final stage of this disease. In addition, we evaluated AR signaling pathway activity. Consistent with previous results, most of our treatment-naïve cases showed high AR activity, indicating a better response to anti-androgen therapy.[@ref10] Compared with other cases, PR305 and PRY04 showed decreased AR activity, suggesting a heterogeneous response. Therefore, careful attention is needed when administering hormonal therapy. Above all, our findings suggest that molecular profiling using a targeted panel could provide valuable information, *i.e*., personalized mutation profiles for actionable targets, thereby contributing to clinical treatment decisions.

Notably, we detected a close link between *KMT2D* and the AR signaling pathway in our cohort using the integrative assays. These results were further confirmed using an additional dataset, TCGA-PRAD, showing that KMT2D expression was positively correlated with AR expression at the mRNA and protein level. Moreover, AR-V7-positive patients had high KMT2D expression levels. KMT2D is a histone lysine methyltransferase involved in the monomethylation of H3K4 residues (histone H3 lysine 4-monomethylation, H3K4me1). We previously concluded that, in PCa, KMT2D epigenetically upregulates LIF receptor alpha (*LIFR*)and Kruppel-like factor 4 (*KLF4*) expression, activating PI3K/AKT and epithelial--mesenchymal transition (EMT) oncogenic pathways and promoting PCa outgrowth and metastasis.[@ref8] Recent studies have reported that KMT2D is a transcriptional coactivator that recognizes target genes via DNA-bound transcription factors.[@ref39] In breast cancer, KMT2D is required for FOXA1, PBX homeobox 1 (PBX1), and estrogen receptor (ER) recruitment and activation and contributes to resistance to PI3Kα inhibitors.[@ref40] Thus, the positive correlation between KMT2D and the AR signaling pathway raises the possibility that KMT2D serves as a transcriptional coactivator and controls AR activation through posttranslational modification of epigenetic regulators. Further research is required to comprehensively clarify the role of KMT2D in PCa.

CONCLUSION {#sec1-5}
==========

We applied an integrative approach to identify the critical genomic and transcriptomic events in 46 routine clinical Chinese PCa samples. This approach is helpful in characterizing retrospective material and analyzing correlations between clinical parameters and molecular changes. More importantly, focused assessments of genomic and transcriptomic features are important for disease pathology research as well as for advancements in personalized medicine.
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T stage, distance metastatic, NCCN risk stratification and EAU risk classification are linked to worse prognosis in our cohort. Survival analysis was performed on Chinese PCa patients treated according to the presence or absence of T stage (**a**), or distance metastatic (**b**), or NCCN risk stratification (**c**), and EAU risk classification (**d**).
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